{"id":"placebo-for-empagliflozin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inactive substance used as a comparator in randomized controlled trials to assess the efficacy of an active drug (in this case, Empagliflozin) by isolating the true drug effect from placebo response and natural disease progression. It allows researchers to determine whether observed clinical benefits are attributable to the active drug's mechanism rather than patient expectation or other non-specific factors.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:50.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials for Empagliflozin efficacy assessment"}]},"trialDetails":[{"nctId":"NCT06554301","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-10-20","conditions":"Pulmonary Arterial Hypertension","enrollment":72},{"nctId":"NCT05013112","phase":"NA","title":"Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-01-01","conditions":"Kidney Transplantation, Metabolic Disorder, Metformin","enrollment":105},{"nctId":"NCT07053319","phase":"PHASE1","title":"SGLT2i, Pioglitazone, and Ketone Production in T2D","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-07-20","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT05182658","phase":"PHASE3","title":"Empagliflozin in Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-06-01","conditions":"Hypertrophic Cardiomyopathy, Heart Failure","enrollment":250},{"nctId":"NCT04906213","phase":"PHASE2","title":"CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Duke University","startDate":"2022-07-25","conditions":"Kidney Transplant; Complications, Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT05726032","phase":"PHASE2","title":"Empagliflozin in Patients With Cirrhosis and Ascites","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-09-11","conditions":"Cirrhosis, Liver Failure","enrollment":20},{"nctId":"NCT06506422","phase":"PHASE2, PHASE3","title":"Empagliflozin Reversal of Arterial StiffnEss in Aging","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-08-18","conditions":"Aging, Arterial Stiffness","enrollment":80},{"nctId":"NCT06229678","phase":"EARLY_PHASE1","title":"Ketones, SGLT2, HFrEF","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01-25","conditions":"Type2diabetes, Heart Failure With Reduced Ejection Fraction","enrollment":71},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT05147090","phase":"PHASE4","title":"Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-02","conditions":"Chronic Hepatitis b, NAFLD, Cirrhosis","enrollment":106},{"nctId":"NCT05426525","phase":"PHASE4","title":"Use of Empagliflozin to Treat Prediabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon State University","startDate":"2022-10-13","conditions":"PreDiabetes, Prediabetic State, Overweight and Obesity","enrollment":60},{"nctId":"NCT06625073","phase":"PHASE4","title":"Randomized Trial of SGLT2i in Heart Transplant Recipients","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-01-20","conditions":"Heart Transplant, Cardiovascular Disease, Kidney Disease","enrollment":200},{"nctId":"NCT03867487","phase":"PHASE2","title":"SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease","status":"NOT_YET_RECRUITING","sponsor":"Justin Ryder","startDate":"2027-05-01","conditions":"Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD","enrollment":40},{"nctId":"NCT06149793","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-01-08","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":8},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT06609356","phase":"EARLY_PHASE1","title":"Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-07-03","conditions":"Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes","enrollment":27},{"nctId":"NCT07038356","phase":"PHASE3","title":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"Christian Schulze","startDate":"2025-12-08","conditions":"Acute Decompensated Heart Failure (ADHF)","enrollment":536},{"nctId":"NCT06992440","phase":"PHASE2","title":"Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Gustavo A Heresi, MD, MS","startDate":"2025-06-26","conditions":"Pulmonary Arterial Hypertension","enrollment":78},{"nctId":"NCT05786443","phase":"PHASE2","title":"Safety and Efficacy of Empagliflozin in Hemodialysis","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-01-31","conditions":"End Stage Renal Disease","enrollment":60},{"nctId":"NCT07112274","phase":"NA","title":"Empagliflozin on Patients With Preserved Heart Failure","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":"Heart Failure","enrollment":50},{"nctId":"NCT06171802","phase":"PHASE4","title":"EMPagliflozin After Aortic Valve Replacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-02-14","conditions":"Aortic Valve Stenosis","enrollment":205},{"nctId":"NCT04447911","phase":"PHASE4","title":"Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-02-04","conditions":"Hyponatremia, SIADH, Liver Failure","enrollment":172},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease","enrollment":47},{"nctId":"NCT06260059","phase":"PHASE4","title":"Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","status":"RECRUITING","sponsor":"Anita Saraf","startDate":"2024-09-17","conditions":"Adult Congenital Heart Disease, Heart Failure","enrollment":40},{"nctId":"NCT06507657","phase":"EARLY_PHASE1","title":"Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-12-12","conditions":"Hypertension, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT06674109","phase":"PHASE4","title":"SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10-15","conditions":"Gout and Hyperuricemia","enrollment":60},{"nctId":"NCT07065357","phase":"PHASE3","title":"Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Hong Kong","startDate":"2025-08-13","conditions":"Metabolic Syndrome","enrollment":160},{"nctId":"NCT05614115","phase":"PHASE1","title":"Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-21","conditions":"End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis","enrollment":62},{"nctId":"NCT07093476","phase":"PHASE3","title":"Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-07-18","conditions":"T2DM, Diabete Type 2, DM","enrollment":171},{"nctId":"NCT05138575","phase":"PHASE2","title":"SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-01-24","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":53},{"nctId":"NCT06110130","phase":"PHASE4","title":"Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD","status":"RECRUITING","sponsor":"Washington D.C. Veterans Affairs Medical Center","startDate":"2024-02-02","conditions":"Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT05610956","phase":"EARLY_PHASE1","title":"Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-01-01","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT05058417","phase":"PHASE2","title":"Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-10-01","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT05960656","phase":"PHASE1","title":"SGLTi, Hepatic Glucose Production and Ketogenesis","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-10-05","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT05972564","phase":"PHASE1, PHASE2","title":"The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-09-06","conditions":"Obesity, Metabolic Syndrome","enrollment":74},{"nctId":"NCT05057806","phase":"EARLY_PHASE1","title":"SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-01-13","conditions":"Type2 Diabetes, Heart Failure With Preserved Ejection Fraction","enrollment":30},{"nctId":"NCT06894784","phase":"PHASE3","title":"A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-04","conditions":"Diabetes Type 1","enrollment":36},{"nctId":"NCT06473844","phase":"NA","title":"Efficacy of SGLT2 Inhibitors in Adults With Sepsis","status":"RECRUITING","sponsor":"Hospital Authority, Hong Kong","startDate":"2025-03-05","conditions":"Sepsis, Inflammation, SGLT2 Inhibitors","enrollment":60},{"nctId":"NCT05254002","phase":"PHASE2","title":"A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-06-23","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":1664},{"nctId":"NCT05671991","phase":"PHASE4","title":"Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-03-01","conditions":"End Stage Renal Disease on Dialysis","enrollment":30},{"nctId":"NCT05084235","phase":"PHASE2","title":"The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure","status":"COMPLETED","sponsor":"Jacob Moller","startDate":"2021-09-02","conditions":"Heart Failure, Obesity","enrollment":191},{"nctId":"NCT05042973","phase":"PHASE2","title":"The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure","status":"COMPLETED","sponsor":"Jacob Moller","startDate":"2021-09-02","conditions":"Obesity, Heart Failure","enrollment":165},{"nctId":"NCT05504226","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-10-12","conditions":"Type 2 Diabetes","enrollment":214},{"nctId":"NCT05504239","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-09-27","conditions":"Type 2 Diabetes","enrollment":235},{"nctId":"NCT04509674","phase":"PHASE3","title":"EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-12-16","conditions":"Myocardial Infarction","enrollment":6522},{"nctId":"NCT05553938","phase":"PHASE1","title":"Effects of Acute and Chronic Empagliflozin Heart Failure","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-08-04","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT06249945","phase":"PHASE4","title":"EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-03-05","conditions":"Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis","enrollment":150},{"nctId":"NCT06249932","phase":"PHASE4","title":"Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-03-13","conditions":"Heart Failure with Reduced Ejection Fraction, End Stage Renal Disease on Dialysis","enrollment":95},{"nctId":"NCT04541797","phase":"NA","title":"Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-10-01","conditions":"Type 2 Diabetes, Microvascular Coronary Artery Disease","enrollment":160},{"nctId":"NCT06653738","phase":"PHASE3","title":"Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-05","conditions":"Kidney Stone, Nephrolithiasis, Dietary Exposure","enrollment":380},{"nctId":"NCT06641128","phase":"PHASE4","title":"The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-10-15","conditions":"Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse Reaction","enrollment":44},{"nctId":"NCT06632561","phase":"PHASE4","title":"Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus","status":"COMPLETED","sponsor":"Ashraf Wasfy Beshay Aziz","startDate":"2021-07-26","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":74},{"nctId":"NCT03193684","phase":"PHASE4","title":"Empagliflozin and Hepatic Glucose Metabolism","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-05-20","conditions":"Hepatic Glucose Metabolism","enrollment":72},{"nctId":"NCT03087773","phase":"PHASE3","title":"Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2017-05-11","conditions":"Acute Myocardial Infarction","enrollment":476},{"nctId":"NCT05036317","phase":"PHASE3","title":"Empagliflozin for the Treatment of Postprandial Hypoglycemia","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-03-11","conditions":"Postprandial Hypoglycemia","enrollment":40},{"nctId":"NCT06021145","phase":"PHASE4","title":"Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-04-02","conditions":"Type 1 Diabetes","enrollment":46},{"nctId":"NCT05885074","phase":"PHASE2","title":"Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-01-30","conditions":"Obesity, Weight Loss","enrollment":""},{"nctId":"NCT04233801","phase":"PHASE3","title":"A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-04-15","conditions":"Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT04642261","phase":"PHASE4","title":"Effect of Empagliflozin on Liver Fat in Non-diabetic Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":98},{"nctId":"NCT05977465","phase":"PHASE1, PHASE2","title":"Empagliflozin in Treatment of Peripheral Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-20","conditions":"Diabetic Neuropathy Peripheral","enrollment":50},{"nctId":"NCT04911660","phase":"PHASE2","title":"Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-08-25","conditions":"Kidney Stone","enrollment":50},{"nctId":"NCT05776043","phase":"PHASE3","title":"Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2022-03-15","conditions":"Acute Decompensated Heart Failure","enrollment":1364},{"nctId":"NCT05057819","phase":"PHASE4","title":"Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-12-01","conditions":"Dumping Syndrome, Hypoglycemia, Reactive","enrollment":22},{"nctId":"NCT04461041","phase":"PHASE4","title":"Empagliflozin and Cardiac Remodelling in People Without Diabetes","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2021-04-01","conditions":"Cardiovascular Diseases, Left Ventricular Hypertrophy","enrollment":169},{"nctId":"NCT03554200","phase":"PHASE2","title":"EMPA Acute Heart Failure","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2018-06-11","conditions":"Diabetes Mellitus, Type 2, Acute Heart Failure","enrollment":19},{"nctId":"NCT04450563","phase":"PHASE1","title":"Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-11-02","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT05512130","phase":"EARLY_PHASE1","title":"Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy","status":"UNKNOWN","sponsor":"Washington University School of Medicine","startDate":"2022-08-17","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT03151343","phase":"PHASE3","title":"SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk","status":"COMPLETED","sponsor":"Caroline M Kistorp","startDate":"2017-03-29","conditions":"Type2 Diabetes Mellitus","enrollment":92},{"nctId":"NCT04157751","phase":"PHASE3","title":"A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-05-18","conditions":"Heart Failure","enrollment":530},{"nctId":"NCT03979352","phase":"PHASE3","title":"Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2019-08-01","conditions":"Type1 Diabetes Mellitus","enrollment":28},{"nctId":"NCT05373004","phase":"PHASE2, PHASE3","title":"Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Omar Tarek Elfarargi","startDate":"2023-03","conditions":"Diabetic Nephropathy Type 2","enrollment":212},{"nctId":"NCT03202667","phase":"PHASE2, PHASE3","title":"Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-12-15","conditions":"SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia","enrollment":17},{"nctId":"NCT03030222","phase":"PHASE4","title":"Empagliflozin Impact on Hemodynamics in Patients With Heart Failure","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2017-07-05","conditions":"Heart Failure","enrollment":65},{"nctId":"NCT05109949","phase":"PHASE3","title":"Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2020-03-30","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":72},{"nctId":"NCT03713190","phase":"PHASE2","title":"Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-09-10","conditions":"End Stage Renal Disease","enrollment":25},{"nctId":"NCT04049045","phase":"PHASE2","title":"Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Christian Schulze","startDate":"2019-09-29","conditions":"Acute Decompensated Heart Failure","enrollment":60},{"nctId":"NCT03226457","phase":"PHASE4","title":"SGLT2 Inhibition in Combination With Diuretics in Heart Failure","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2017-12-11","conditions":"Heart Failure, Type 2 Diabetes Mellitus","enrollment":23},{"nctId":"NCT02890745","phase":"PHASE2","title":"The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Henrik Enghusen Poulsen","startDate":"2016-11","conditions":"Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT03351478","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-11-27","conditions":"Type 2 Diabetes Mellitus","enrollment":770},{"nctId":"NCT02932436","phase":"PHASE4","title":"Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2016-10-10","conditions":"Diabetes Mellitus, Type 2, Diastolic Dysfunction","enrollment":144},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT04583813","phase":"PHASE4","title":"Empagliflozin and Atrial Fibrillation Treatment","status":"UNKNOWN","sponsor":"Miulli General Hospital","startDate":"2021-09","conditions":"Atrial Fibrillation, Heart Failure, Obesity","enrollment":400},{"nctId":"NCT03485222","phase":"PHASE4","title":"Are the \"Cardiac Benefits\" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Cardiovascular Diseases","enrollment":84},{"nctId":"NCT03485092","phase":"PHASE4","title":"Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-03-16","conditions":"Heart Failure, Diabetes Mellitus","enrollment":105},{"nctId":"NCT03027960","phase":"PHASE1","title":"Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-06-27","conditions":"Heart Failure, Type II; Diabetes","enrollment":21},{"nctId":"NCT02597049","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":424},{"nctId":"NCT03173963","phase":"PHASE3","title":"Empaglifozin in Early Diabetic Kidney Disease","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-05-27","conditions":"Diabetic Kidney Disease, Diabetes Mellitus Type 2","enrollment":""},{"nctId":"NCT03198585","phase":"PHASE2","title":"Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Morten Schou","startDate":"2017-06-29","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":190},{"nctId":"NCT02798744","phase":"PHASE4","title":"SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-12","conditions":"Diabetes Mellitus, Type 2","enrollment":68},{"nctId":"NCT02833415","phase":"PHASE4","title":"Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-03","conditions":"Obesity, Visceral","enrollment":40},{"nctId":"NCT03152552","phase":"PHASE2","title":"A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-07-25","conditions":"Diabetes Mellitus and Heart Failure","enrollment":125},{"nctId":"NCT04061200","phase":"PHASE4","title":"Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria","status":"UNKNOWN","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-11-01","conditions":"Type 2 Diabetes With Renal Manifestations","enrollment":80},{"nctId":"NCT03093103","phase":"PHASE2","title":"Empagliflozin and Renal Oxygenation in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2017-03-16","conditions":"Nephropathy","enrollment":45},{"nctId":"NCT02874807","phase":"PHASE2, PHASE3","title":"Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-09-05","conditions":"SIADH","enrollment":88},{"nctId":"NCT02589639","phase":"PHASE4","title":"Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-10-28","conditions":"Diabetes Mellitus, Type 2","enrollment":269},{"nctId":"NCT02728453","phase":"PHASE4","title":"SGLT2 Inhibition and Left Ventricular Mass","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2016-04-27","conditions":"Diabetes Mellitus Type 2","enrollment":7},{"nctId":"NCT03157414","phase":"PHASE4","title":"Empagliflozin in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-11-07","conditions":"Diabetes Mellitus, Renal Insufficiency, Safety Issues","enrollment":49},{"nctId":"NCT03132181","phase":"PHASE2","title":"Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2017-04-24","conditions":"Diabetes Mellitus Type 2 (T2DM)","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":857,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo","Sugar pill"],"phase":"marketed","status":"active","brandName":"Placebo (for Empagliflozin)","genericName":"Placebo (for Empagliflozin)","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials. Used for Control arm in clinical trials for Empagliflozin efficacy assessment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}